We propose a novel Myocardial Injury Summary Score (MISS) integrating the 4 biomarkers suggested by the 2013 American College of Cardiology/ American Heart Association guidelines for management of heart failure. In this case series, we examined 4 heart failure patients who received treatment guided by the biomarker results and 4 patients who received routine clinical management with no information about the biomarkers. Most of the patients receiving biomarker-guided management had medications adjusted based on the biomarker values, while no changes were recommended for patients in the biomarker-blinded category. This case series suggests that biomarker-guided therapy with serial biomarker values leads to timely therapeutic adjustment and that biomarker values as a composite score can be used effectively to measure the severity of heart failure.
A bout 5.7 million Americans suff er from heart failure (HF) (1) , and the mortality rate is approximately 50% over 5 years for a patient newly diagnosed with HF (2) . Th e prevalence of HF has been documented to be increasing, given prolonged survival due to better treatment modalities (3) . Cardiac biomarkers have been recommended as prognostic and diagnostic tools in the clinical management of HF, and American College of Cardiology/American Heart Association guidelines have suggested the use of 4 biomarkers-B-type natriuretic peptide (BNP), troponin, galectin-3, and suppression of tumorigenicity 2 (ST2)-to guide the prognosis of patients with HF (4). Management of HF with routine biomarkers as part of the follow-up was shown to increase the survival benefi t for these patients (5) . We incorporated the 4 recommended biomarkers into the Myocardial Injury Summary Score (MISS) (6), a novel score to measure the severity of HF. In this case series, we examined 8 HF patients who received either treatment guided by the biomarker results or routine clinical management with no information about the biomarkers. Th is study was approved by the Baylor institutional review board and funded by the Cardiovascular Research Review Committee.
METHODS
HF patients who were ambulatory with an ejection fraction <40% and an estimated glomerular fi ltration rate ≥30 mL/ min/1.73 m 2 were included in this study. Th e patients were randomized to either management based on the biomarkers obtained at each visit or by standard clinical management, where the clinicians were blinded to the results of the biomarkers. Th e advocated therapeutic management for the biomarker-guided therapy is detailed in Table 1 .
For each patient, the 4 biomarker values were integrated into a novel score to measure the severity of HF. Th e basic metric is the ratio of the biomarker value at the current offi ce visit to the baseline value obtained during the previous offi ce visit:
Personalized treatment of heart failure with biomarker guidance using a novel disease severity score 
Based on the pharmacologic regimen of the HF drugs, a therapeutic intensity index was formulated for each patient after every visit. Th e index was based on HF drug classes and their corresponding doses, which ranged in intensity from 1 to 3. Th e summed therapeutic intensity index ranges from 0 to 24, with 24 being the highest intensity of medical management. Table 2 provides the details of the drugs and their corresponding intensity scores.
RESULTS
Four of the 8 patients were randomized to the biomarkerguided management (B) arm, and the remaining 4 were randomized to the usual clinical management (UC) arm. Th e median age of patients was 57.5 years (range 52-71) in the B arm and 56 years (range 43-65) in the UC arm. Th ere were 5 men (3 in B and 2 in UC) and 3 women (1 in B and 2 in UC). Th e etiology of HF was considered ischemic in 6 of the patients included in this study (3 each in the B and UC arms). Th ree of the 4 patients randomized to the B arm had diabetes, while only one patient in the UC arm had diabetes. All patients included in this case series had hypertension, and 2 and 3 patients in the B and UC arms had dyslipidemia, respectively. Th e demographic details and comorbidities are shown in Table 3 . Table 4 shows the therapeutic management and MISS for each of the 8 patients. Figure 1 shows the baseline MISS segregated by age, and Figures 2 and 3 show the changes in the MISS and therapeutic intensity index for each patient. For patients on biomarker-guided management, the pharmacologic transformation corrects the observed right-skew of the MISS distribution, which is constructed from biomarkers bounded by zero, but potentially having relatively large values. A biomarker having the same value after a patient receives treatment as before the patient receives treatment has a ratio of 1 and a log score of 0. Further, biomarkers changing by a scaled factor of 10 have log 10 values between -1 and +1, which is appealing. For the baseline visit, the MISS score was calculated using the upper limit of normal of the corresponding biomarker as the denominator. II  III  III  III  II  II  II 
DISCUSSION
We found in this case series that it was feasible to randomize patients to either a biomarker-informed or -blinded approach for ambulatory management of HF patients. Additionally, we found that it was feasible to calculate and monitor a novel multimarker score refl ecting HF disease severity. Lastly, we were able to calculate an integrated measure of therapeutic intensity, which changed modestly in the patients with biomarker-guided management. Th e results showed that biomarker-guided therapy led to timely therapeutic adjustment that might be benefi cial to the patient with HF and might help with systematic therapeutic management.
Several randomized controlled trials have shown that targeting the biomarkers resulted in better prognostics and diagnostics for HF patients. Th e Barcelona Bio-Heart Failure Risk Calculator incorporating ST2, N-terminal pro BNP, and troponin T biomarkers allowed better prediction of death among HF patients (7) . Compared to the Seattle Heart Failure Model, the Penn Heart Failure Study found that a multimarker score incorporating biomarkers increased the ability to predict adverse outcomes in ambulatory patients with chronic HF (8) . A post hoc analysis including 151 patients with chronic HF showed that baseline measurement of 3 biomarkers (ST2, growth/diff erentiation factor 15, and highly sensitive assay for troponin T) increased the overall prognostic ability, while serial ST2 measurement helped predict change in left ventricular function (9) . In older patients with stable HF, soluble isoform of ST2 was found to be an independent predictor of worsening HF, suggesting an association between increasing values of soluble isoform of ST2 and progressive myocardial failure (10) . Titrating therapy based on the serial values of natriuretic peptides was proven to be associated with a signifi cant reduction in mortality in a metaanalysis, including 6 randomized clinical trials with HF patients (11) , and targeting these biomarkers has been shown to benefi t HF patients. In our case series, we assimilated the 4 biomarkers into a composite score to guide the prognosis of these patients while managing the therapeutics based on the biomarkers, providing us an option to practice precision medicine. Th e recent GUIDE-IT (Guiding Evidence-Based Th erapy Using Biomarker Intensifi ed Treatment in Heart Failure) trial, a comparison of biomarkerguided therapy and usual care for high-risk HF patients based on a single biomarker (BNP), was terminated early, as no diff erence was noted in the primary outcome between the 2 groups in the interim analysis (12) . However, given the heterogeneity of HF, our composite score incorporates 4 biomarkers that assess diff erent pathologies of HF. Along with the biomarkers, use of clinical characteristics and echocardiographic fi ndings have been suggested to enhance the concept of personalized management in the HF domain of cardiovascular disease (13, 14) . Our study has all the limitations of small pilot studies testing the feasibility of a new randomized approach with novel assessments of both exposures and endpoints. As we did not order renal function tests during each study visit, we were unable to make inferences regarding kidney function over time. We recognize that these measures will be positioned with clinical judgment and cannot predict many individual scenarios. For example, we observed several integrated MISS scores in the stable range despite having several cases of decompensation that were not signaled by a meaningful change in the score. 
